Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the "Company") today reported financial results and provided key updates for the fourth quarter and year ended December 31, 2025.
Financial guidance assumes a standard FDA review for olezarsen with a Q4 approval, though management notes that a priority ...
The headline numbers for Ionis Pharmaceuticals (IONS) give insight into how the company performed in the quarter ended ...
Ooops... Something went wrong while loading this page.
Good morning, and welcome to Ionis' Fourth Quarter and Full Year 2025 Financial Results Conference Call. As a reminder, this call is being recorded. At this time, I would like to turn the call over to ...
CARLSBAD, Calif. (AP) — CARLSBAD, Calif. (AP) — Ionis Pharmaceuticals Inc. (IONS) on Wednesday reported a loss of $229 million in its fourth quarter. On a per-share basis, the Carlsbad, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results